Lodise Thomas P, Patel Nimish, Lomaestro Ben M, Rodvold Keith A, Drusano George L
Dept. of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Ave., Albany, NY 12208, USA.
Clin Infect Dis. 2009 Aug 15;49(4):507-14. doi: 10.1086/600884.
Data suggest that higher doses of vancomycin can increase the risk of nephrotoxicity. No study has been undertaken to determine the pharmacodynamic index (ie, the area under the curve [AUC] or the trough value) that best describes the relationship between vancomycin exposure and onset of nephrotoxicity.
A retrospective study was conducted among patients who received vancomycin for a suspected or proven gram-positive infection during the period from 1 January 2005 through 31 December 2006 at Albany Medical Center Hospital. Patients were included in our study if they (1) were > or =18 years old, (2) had an absolute neutrophil count of > or =1000 cells/mm(3), (3) received vancomycin for >48 h, (4) had 1 vancomycin trough level collected within 96 h of vancomycin therapy, and (5) had a baseline serum creatinine level of <2.0 mg/dL. Patients were excluded if they (1) had a diagnosis of cystic fibrosis, (2) received intravenous contrast dye within 7 days of starting vancomycin or during therapy, or (3) required vasopressor support during therapy. Demographics, comorbid conditions, and treatment data were collected. The highest observed vancomycin trough value within 96 h of initiation of vancomycin therapy and the estimated vancomycin AUC were analyzed as measures of vancomycin exposure. The vancomycin AUC value from 0 to 24 h at steady state (in units of mg x h/L) for each patient was estimated by use of the maximum a posteriori probability Bayesian procedure in ADAPT II. Nephrotoxicity was defined as an increase in serum creatinine level of 0.5 mg/dL or 50%, whichever was greater, following initiation of vancomycin therapy. Logistic and Cox proportional hazards regression models identified the vancomycin pharmacodynamic index that best describes the relationship between vancomycin exposure and toxicity.
During the study period, 166 patients met the inclusion criteria. Both initial vancomycin trough values and 0-24-h at steady state AUC values were associated with nephrotoxicity in the bivariate analyses. However, the vancomycin trough value, modeled as a continuous variable, was the only vancomycin exposure variable associated with nephrotoxicity in the multivariate analyses.
The results indicate that a vancomycin exposure-toxicity response relationship exists. The vancomycin trough value is the pharmacodynamic index that best describes this association.
数据表明,较高剂量的万古霉素会增加肾毒性风险。尚未进行研究以确定最能描述万古霉素暴露与肾毒性发生之间关系的药效学指标(即曲线下面积[AUC]或谷值)。
对2005年1月1日至2006年12月31日期间在奥尔巴尼医学中心医院因疑似或确诊革兰氏阳性感染而接受万古霉素治疗的患者进行了一项回顾性研究。符合以下条件的患者被纳入我们的研究:(1)年龄≥18岁;(2)绝对中性粒细胞计数≥1000个细胞/mm³;(3)接受万古霉素治疗超过48小时;(4)在万古霉素治疗96小时内采集过1次万古霉素谷值水平;(5)基线血清肌酐水平<2.0mg/dL。符合以下条件的患者被排除:(1)诊断为囊性纤维化;(2)在开始万古霉素治疗后7天内或治疗期间接受静脉造影剂;(3)治疗期间需要血管升压药支持。收集了人口统计学、合并症和治疗数据。分析了万古霉素治疗开始后96小时内观察到的最高万古霉素谷值以及估计的万古霉素AUC,作为万古霉素暴露的指标。使用ADAPT II中的最大后验概率贝叶斯程序估计每位患者稳态下0至24小时的万古霉素AUC值(单位为mg·h/L)。肾毒性定义为万古霉素治疗开始后血清肌酐水平升高0.5mg/dL或升高50%(以较高者为准)。逻辑回归和Cox比例风险回归模型确定了最能描述万古霉素暴露与毒性之间关系的万古霉素药效学指标。
在研究期间,166例患者符合纳入标准。在双变量分析中,初始万古霉素谷值和稳态下0至24小时AUC值均与肾毒性相关。然而,在多变量分析中,作为连续变量建模的万古霉素谷值是唯一与肾毒性相关的万古霉素暴露变量。
结果表明存在万古霉素暴露-毒性反应关系。万古霉素谷值是最能描述这种关联的药效学指标。